El interés en corto de ProCap Acquisition da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de ProCap Acquisition. Los datos de interés en corto se actualizan cada dos semanas.

ProCap Acquisition (NASDAQ:PCAPU) Bolsa, Informe de interés en corto

ProCap Acquisition Corp is a blank check company.

Leather,Wallet,Full,Of,Money,On,Wooden,Table,-,One

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Bonds

Markets

$BTC

PCAPU

El defensor de Bitcoin (CRYPTO: BTC) y gestor de fondos Anthony Pompliano ha lanzado una dura advertencia sobre la trayectoria fiscal de Estados Unidos.

Bitcoin sube mientras EE. UU. se hunde en deuda, alerta Anthony Pompliano

ProCap Acquisition Corp

Citigroup analyst Christopher Danely maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral and lowers the price target from $60 to $54.

News

Price Target

Analyst Ratings

Citigroup Maintains Neutral on ON Semiconductor, Lowers Price Target to $54

WIIM

Jacobs Solutions shares are trading higher after the company reported better-than-expected Q3 financial results.

The hit animated series "South Park," which is back <a href="https://www.benzinga.com/news/politics/25/07/46615709/south-park-goes-anti-trump-with-satan-jesus-president-white-house-says-show-hasnt-been-relevant-for-20-years">for its 27th season,</a> wasted no time making fun of President Donald Trump and the ongoing legal saga between the president and Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) that owns the rights to the show.
A new restructuring of Paramount management could result in executives keeping a closer watch on the series after upsetting Trump in the first episode of the new season.
What Happened: Paramount <a href="https://www.benzinga.com/m-a/25/07/46619864/paramount-global-stock-jumps-after-fcc-approves-8-billion-merger-with-skydance">completed a merger</a> with Skydance Media, a deal that was signed off on after much delay by the Trump administration.
A past lawsuit by Trump against Paramount over its "60 Minutes" segment proved controversial, as did the recent firing of Stephen Colbert and cancellation of the "Late Show with Stephen Colbert" scheduled for May 2026.
Paramount has restructured its management teams following the merger. Many of the scripted production operations for series will fall under the Paramount TV Studios division, led by Dana Goldberg, <a href="https://deadline.com/2025/08/south-park-production-george-cheeks-paramount-structure-1236478047/">reported</a> Deadline.
One of the exceptions is "South Park," which will become part of the items managed by George Cheeks, chairman of TV Media.
Cheeks will oversee "South Park," along with items from CBS Network, CBS News &amp; Stations, CBS Sports, CBS Studios, Nickelodeon, Comedy Central, MTV and BET Studios.
Under the new management structure, Goldberg will oversee the production of most shows catered to the company's streaming segment. At the same time, Cheeks will handle the majority of shows primarily for linear networks owned by Paramount.
Read Also: <a href="https://www.benzinga.com/news/entertainment/25/07/46769277/trump-jokes-on-south-park-help-lift-viewership-by-68">Donald Trump Jokes On &#8216;South Park&#8217; Help Lift Viewership By 68%</a>
Why It's Important: Cheeks will be in charge of "South Park," oversee the final episodes of "The Late Show with Stephen Colbert," and oversee "The Daily Show." All three of these shows are known for making fun of Trump.
Cheeks was also in charge of the unit that decided to cancel Colbert's show. Paramount cited the cancellation as a financial decision, but it occurred around the time that Colbert said Paramount was paying bribes by settling with Trump. The president, who has often been critical of Colbert in the past, praised the move by Paramount.
"South Park" was recently renewed under a five-year, $1.5 billion deal that grants Paramount new episodes for Comedy Central, as well as streaming rights for Paramount+ for both new and old episodes.
The animated series, known to make fun of Trump and other politicians, sometimes crosses the line.
The question for fans and showrunners Matt Stone and Trey Parker is what role Cheeks will play in making sure the show doesn't upset the president or push the boundaries too far.
So far, no executives have been able to stop the show when it comes to its unique form of comedy, even in the recent episode that made fun of the president's male anatomy.
Cheeks is in a challenging position as he&#8217;s leading a show he helped cancel and two shows the White House would most likely love to see disappear, including one that Paramount just paid more than $1 billion to keep the show's founders happy.
PARA Price Action: Paramount stock is down 5.4% to $11.64 on Tuesday versus a 52-week trading range of $9.95 to $13.59. Paramount stock is up 10.1% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46496489/elizabeth-warren-demands-paramount-explain-colberts-late-show-cancellation-america-deserves-to-know">Elizabeth Warren Demands Paramount Explain Colbert&#8217;s &#8216;Late Show&#8217; Cancellation—&#8217;America Deserves To Know&#8217;</a></li>
</ul>
Photo: Shutterstock

Entertainment

Politics

Media

PARA

PARAA

South Park On Probation? Animated Hit Show Placed Under Watch Of The Man Who Fired Colbert

Inspire Medical Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) stock is plunging after the company released its second-quarter earnings <a target="_blank" href="https://www.benzinga.com/quote/INSP/earnings" rel="noreferrer noopener">and cut its annual guidance</a>.
Track INSP <a href="https://www.benzinga.com/quote/INSP">s</a><a href="https://www.benzinga.com/quote/INSP" target="_blank" rel="noreferrer noopener">tock&#8217;s live prices here.</a>
The company, which focuses on minimally invasive solutions for obstructive sleep apnea, reported sales of $217.09 million, up 11% year-over-year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $214.48 million</a>.
Inspire Medical swung into a loss of 12 cents per share, a shift from an income of 32 cents a year ago.
Adjusted earnings per share were 45 cents compared to the consensus <a target="_blank" href="https://www.benzinga.com/pressreleases/25/08/g46839062/inspire-medical-systems-inc-announces-second-quarter-2025-financial-results-and-updates-2025-outlo" rel="noreferrer noopener">estimate of 21 cents</a>.
The company initiated the full launch of the Inspire V neurostimulation system in the U.S. In August 2024, the FDA approved the Inspire V therapy system, which includes the next-generation neurostimulator and the associated Bluetooth patient remote <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42097098/inspire-medicals-strong-2025-outlook-and-upcoming-inspire-v-launch-earns-analyst-upgrade" rel="noreferrer noopener">and physician programmer</a>.
&#8220;However, the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year,&#8221; said Tim Herbert, chairman and CEO of Inspire.
&#8220;Importantly, we believe the operational headwinds are temporary, and actions are underway to address them,&#8221; continued Herbert.
Gross margin was 84% for the second quarter of 2025 compared to 84.8% in the second quarter of 2024. The decrease is primarily due to a $2.1 million charge associated with excess components inventory related to Inspire IV.
Operating loss was $3.3 million compared to operating income of $5.1 million a year ago.
Investors should note that in December 2024, the FDA approved Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep <a href="https://www.benzinga.com/25/01/42896803/medicare-to-cover-eli-lillys-weight-loss-drug-zepbound-for-obstructive-sleep-apnea-treatment" target="_blank" rel="noreferrer noopener">apnea (OSA) and obesity</a>. 
Guidance: Inspire Medical Systems lowered its fiscal 2025 earnings per share from&nbsp;$2.20-$2.30&nbsp;to&nbsp;40 cents-50 cents&nbsp;compared to the consensus of&nbsp;$2.27.
The company also cut its 2025 sales guidance from $940 million-$955&nbsp;million to&nbsp;$900 million-$910 million, versus the consensus of $949.36 million.
The company maintains its full-year 2025 gross margin guidance of 84% to 86%.
<h2 class="wp-block-heading"><a href="https://www.benzinga.com/quote/INSP/analyst-ratings">Analysts Reactions:</a></h2>
Keybanc downgraded the stock from Overweight to Sector Weight.
JPMorgan downgraded the stock from Overweight to Neutral and lowered the price forecast from&nbsp;$195&nbsp;to&nbsp;$110.
Stifel maintained the stock with a Hold and lowered the price forecast from&nbsp;$175&nbsp;to&nbsp;$140.
Piper Sandler maintained the stock with an Overweight and lowered the price forecast from&nbsp;$233&nbsp;to&nbsp;$150.
RBC Capital maintained the stock with an Outperform and lowered the price target from&nbsp;$215&nbsp;to&nbsp;$180.
UBS maintained the stock with a Buy and lowered the price forecast from $270 to&nbsp;$230.
Lake Street maintained the stock a Buy rating and lowered the price forecast from $270 to&nbsp;$150.
Wells Fargo maintained the stock with an Equal-Weight and lowered the price forecast from&nbsp;$174&nbsp;to&nbsp;$101.
Truist Securities downgraded the stock from Buy to Hold and lowered the price forecast from&nbsp;$190&nbsp;to&nbsp;$125.
INSP Price Action: Inspire Medical Systems stock is down 41.90% at $76.50&nbsp;at publication on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/08/46849305/spotify-to-raise-premium-prices-in-select-markets-starting-september-spot-shares-gained-over-5-on-monday" target="_blank" rel="noreferrer noopener">Spotify To Raise Premium Prices In Select Markets Starting September: SPOT Shares Gained Over 5% On Monday</a></li>
</ul>

Analyst Color

Earnings

Guidance

Downgrades

Health Care

Movers

Trading Ideas

General

INSP

Inspire Medical Plunges On Outlook Cut, Weak V System Rollout: Analysts React

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday.
The Dow traded up 0.12% to 44,228.65 while the NASDAQ declined 0.24% to 21,003.87. The S&amp;P 500 also fell, dropping, 0.15% to 6,320.30.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/08/46856527/this-block-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-tuesday">This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday</a>
Leading and Lagging Sectors Consumer staples shares jumped by 0.4% on Tuesday.
In trading on Tuesday, information technology stocks fell by 1.1%.
Top Headline
The ISM services PMI declined to 50.1 in July from 50.8 in the previous month, compared to estimates of 51.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) shares shot up 104% to $1.9052 after the company announced a $127 million engineering, procurement, and construction agreement.</li>
<li>Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) got a boost, surging 103% to $8.52 after the company announced it will be acquired for approximately $412 million following a merger agreement with Serb Pharmaceuticals.</li>
<li>Ameresco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) shares were also up, gaining 36% to $22.75 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares dropped 52% to $0.8634 after the company withdrew its guidance and announced several senior leadership changes.</li>
<li>Shares of Inspire Medical Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) were down 41% to $76.26 after the company reported worse-than-expected second-quarter GAAP EPS results and cut its FY25 guidance below estimates. Multiple analysts downgraded the stock following the report.</li>
<li>Ichor Holdings, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICHR#NASDAQ">ICHR</a>) was down, falling 30% to $14.00 after the company reported worse-than-expected second-quarter adjusted EPS results and issued third-quarter adjusted EPS guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $65.66 while gold traded up 0.4% at $3,438.60.
Silver traded up 1.5% to $37.900 on Monday, while copper fell 0.9% to $4.3965.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 rose 0.26%, while Spain's IBEX 35 Index slipped 0.01%. London's FTSE 100 rose 0.21%, Germany's DAX 40 gained 0.50% and France's CAC 40 slipped 0.01% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei 225 gaining 0.64%, Hong Kong's Hang Seng gaining 0.68%, China's Shanghai Composite gaining 0.96% and India's BSE Sensex falling 0.38%.
Economics
<ul class="wp-block-list">
<li>The S&amp;P Global US Services PMI increased to 55.7 in July from 52.9 in the previous month.</li>
<li>The US trade deficit shrank to $60.2 billion in June versus a revised $71.7 billion gap in the previous month and versus estimates of a $61.6 billion shortfall.</li>
<li>The RealClearMarkets/TIPP Economic Optimism Index climbed to 50.9 in August from 48.6 in the previous month.</li>
<li>The ISM Services PMI declined to 50.1 in July from 50.8 in the previous month, compared to estimates of 51.5.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/08/46792424/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

AMRC

ICHR

SMXT

YMAB

Nasdaq Down 50 Points; ISM Services PMI Declines In July

Fidelity National Information Services shares are trading lower following the release of its Q2 financial results.

<a href="https://www.bloomberg.com/news/articles/2025-08-05/musk-seeks-dismissal-of-suit-over-his-7-5-billion-tesla-stock-sale?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-08-05/musk-seeks-dismissal-of-suit-over-his-7-5-billion-tesla-stock-sale?srnd=homepage-americas</a>

TSLA

'Musk Seeks Dismissal of Lawsuit Over His $7.5 Billion Tesla Stock Sale'- Bloomberg

FANG

Diamondback Energy shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results.

Management

FOUR

On August 5, 2025, Nancy Disman Informed Shift4 Payments Of Her Intent To Resign From Her Position As CFO Effective September 1, 2025; Christopher N. Cruz Appointed As New CFO

Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported worse-than-expected second-quarter financial results and <a href="https://www.benzinga.com/quote/BRKR/earnings">cut its FY25 guidance on Monday.</a>
Bruker reported quarterly earnings of 32 cents per share which missed the analyst consensus estimate of 44 cents per share. The company reported quarterly sales of $797.40 million which missed the analyst consensus estimate of $810.43 million.
Bruker cut its FY2025 adjusted EPS guidance from $2.40-$2.48 to $1.95-$2.05 and also lowered FY2025 sales guidance from $3.480 billion-$3.550 billion to $3.430 billion-$3.500 billion.
Frank H. Laukien, Bruker&#8217;s President and CEO, said, &#8220;Life-science research instruments demand is under pressure at the moment. Our second quarter came in below expectations, as we experienced challenging demand conditions in the US academic market, as well as in biopharma and industrial markets. Tariffs and a stiff currency headwind could not yet be compensated for by our mitigating price, supply chain and cost actions in the second quarter. We are lowering our financial guidance for FY 2025, while we gain improved visibility into US academic funding trends, China stimulus, finalized tariffs, as well as into the timing of a recovery in biopharma drug discovery and industrial research instruments demand.&#8221;
Bruker shares fell 4% to trade at $33.32 on Tuesday.
These analysts made changes to their price targets on Bruker following earnings announcement.
<ul class="wp-block-list">
<li>Stifel analyst Daniel Arias maintained Bruker with a Hold and lowered the price target from $48 to $40.</li>
<li>Wells Fargo analyst Brandon Couillard maintained Bruker with an Overweight rating and lowered the price target from $60 to $50.</li>
</ul>
Considering buying BRKR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/BRKR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05134522/image-73-1024x592.png" alt="" class="wp-image-1015581" style="width:687px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05134522/image-73-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05134522/image-73-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05134522/image-73-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05134522/image-73.png 1120w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/08/46825110/top-2-financial-stocks-that-may-collapse-this-month">Top 2 Financial Stocks That May Collapse This Month</a></li>
</ul>
Photo via Shutterstock

BRKR

These Analysts Slash Their Forecasts On Bruker After Weaker-Than-Expected Q2 Results

Archer-Daniels-Midland shares are trading higher after the company reported a Q2 adjusted EPS beat.

<a href="https://www.ft.com/content/dd50f413-762e-4388-a2a1-fb8b22408447">https://www.ft.com/content/dd50f413-762e-4388-a2a1-fb8b22408447</a>

'Donald Trump readies fresh sanctions against Russia's shadow fleet'- Financial Times

Craig-Hallum analyst Jeremy Hamblin upgrades Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) from Hold to Buy and announces $900 price target.

Upgrades

AXON

Craig-Hallum Upgrades Axon Enterprise to Buy, Announces $900 Price Target

Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) reported better-than-expected second-quarter <a href="https://www.benzinga.com/quote/AXSM/earnings">financial results on Monday</a>.
Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.
&#8220;Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline. We are excited by the recent approval and launch of SYMBRAVO for migraine, and are pleased with the accelerating performance of AUVELITY for depression and SUNOSI for excessive daytime sleepiness,&#8221; said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.
Axsome Therapeutics shares fell 3.4% to trade at $102.89 on Tuesday.
These analysts made changes to their price targets on Axsome Therapeutics following earnings announcement.
<ul class="wp-block-list">
<li>RBC Capital analyst Leonid Timashev maintained Axsome Therapeutics with an Outperform rating and raised the price target from $184 to $189.</li>
<li>B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $173 to $176.</li>
</ul>
Considering buying AXSM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/AXSM/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-1024x601.png" alt="" class="wp-image-1015572" style="width:639px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72.png 1145w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/08/46825110/top-2-financial-stocks-that-may-collapse-this-month"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/08/46825110/top-2-financial-stocks-that-may-collapse-this-month">Top 2 Financial Stocks That May Collapse This Month</a></li>
</ul>
Photo via Shutterstock

AXSM

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Craig-Hallum analyst Richard Shannon downgrades Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) from Buy to Hold and announces $6 price target.

NVTS

Craig-Hallum Downgrades Navitas Semiconductor to Hold, Announces $6 Price Target

Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) stock plunged Tuesday after it reported fiscal second-quarter 2025 results.
The company reported quarterly gross revenue growth of 17% year-on-year (Y/Y) to $966.20 million, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of&nbsp;$982.95 million.&nbsp;
The payment processing company&#8217;s adjusted EPS of $1.10 missed the&nbsp;<a target="_blank" href="https://investors.shift4.com/financial-information" rel="noreferrer noopener">analyst consensus estimate</a> of $1.26.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/12/42560428/consumer-finance-watchdog-cracks-down-on-credit-card-sneaky-fees-and-false-promises" rel="noreferrer noopener">Consumer Finance Watchdog Cracks Down on Credit Card Sneaky Fees and False Promises</a>
Payments-based revenue improved from $755.8 million a year ago to $868.5 million. Subscription revenue was $97.7 million, up from $71.2 million a year ago.
Gross revenue minus network fees improved to $413.4 million versus $320.6 million a year ago, up 29% Y/Y.
End-to-end payment volume climbed 25%&nbsp;Y/Y&nbsp;to $50.1 billion. Adjusted EBITDA improved 26%&nbsp;Y/Y&nbsp;to $205.1 million.&nbsp;The margin declined 100 bps to 50%.
Shift4 CEO Taylor Lauber said the company delivered strong second-quarter results, achieving record payment volume, revenue, and adjusted EBITDA. He credited the growth to stable payment spreads, a more diversified business mix, and strong performance across key verticals like hotels, restaurants, and entertainment.
Lauber highlighted the successful close of the Global Blue acquisition, which added a new vertical, luxury retail, and expanded Shift4&#8217;s reach to six continents. He expects Global Blue to contribute $330 million in revenue and $125 million in adjusted EBITDA for the rest of 2025, significantly boosting the company&#8217;s cross-sell opportunity.
He also announced a leadership change. CFO Nancy Disman will retire at year-end and rejoin the board, while Chris Cruz, a longtime board member and investor, will step in as the new CFO. Lauber reaffirmed Shift4&#8217;s progress toward its medium-term targets, including a $1 billion free cash flow run rate.
<h2 class="wp-block-heading">Outlook</h2>
Shift4&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">expects fiscal 2025</a> gross revenue&nbsp;minus network fees outlook of $1.965 billion-$2.035 billion (prior $1.35 billion–$1.36 billion).
The company expects fiscal end-to-end payment volume of $200 billion-$220 billion (prior $164 billion–$166 billion).
It&nbsp;projects a fiscal adjusted EBITDA of $965 million-$990 million (prior $677 million–$688 million).
Shift4&nbsp;expects third-quarter gross revenue&nbsp;minus network fees of ~$590 million and adjusted EBITDA of ~$290 million.
Price Action: FOUR stock is trading lower by 17.7% to $84.12 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/08/46856226/globalfoundries-navigates-weak-outlook-as-mobile-device-revenue-declines" target="_blank" rel="noreferrer noopener">GlobalFoundries Navigates Weak Outlook As Mobile Device Revenue Declines</a></li>
</ul>
Photo via Shutterstock

Why Is Shift4 Payments Stock Falling Tuesday?

STIM

STIM stock has given up its prior loss. Neuronetics shares were trading lower after the company reported a Q2 EPS miss.

Roth Capital analyst Craig Irwin reiterates Willdan Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) with a Buy and raises the price target from $62 to $103.

Reiteration

WLDN

Roth Capital Reiterates Buy on Willdan Group, Raises Price Target to $103

BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) reported a narrower loss for the second quarter <a href="https://www.benzinga.com/quote/BNTX/earnings">on Monday</a>.
The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.
The COVID-19 vaccine maker reported sales of $295.69 million (260.8 million euros), compared to 128.7 million euros a year ago, beating the consensus of $147.90 million.
BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion euros and revenue phasing primarily concentrated in the last three to four months.
"In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by strengthening the two pillars of our oncology strategy," said Ugur Sahin, CEO and Co-Founder of BioNTech, in a statement Monday.
BioNTech shares gained 0.9% to trade at $111.05 on Tuesday.
These analysts made changes to their price targets on BioNTech following earnings announcement.
<ul class="wp-block-list">
<li>B of A Securities analyst Tazeen Ahmad maintained BioNTech with a Buy and raised the price target from $126 to $134.</li>
<li>Wells Fargo analyst Mohit Bansal maintained the stock with an Overweight rating and lowered the price target from $170 to $150.</li>
</ul>
Considering buying BNTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/BNTX/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="565" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133443/image-71-1024x565.png" alt="" class="wp-image-1015562" style="width:681px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133443/image-71-1024x565.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133443/image-71-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133443/image-71-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133443/image-71.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/08/46825110/top-2-financial-stocks-that-may-collapse-this-month">Top 2 Financial Stocks That May Collapse This Month</a></li>
</ul>
Photo via Shutterstock

BNTX

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/08/25</td>
<td>$310.00</td>
<td>$108.1K</td>
<td>10.6K</td>
<td>49.3K</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/05/25</td>
<td>$425.00</td>
<td>$40.7K</td>
<td>14</td>
<td>2.3K</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$9.67</td>
<td>$70.2K</td>
<td>74.3K</td>
<td>1.8K</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/08/25</td>
<td>$118.00</td>
<td>$26.2K</td>
<td>2.1K</td>
<td>986</td>
</tr>
<tr>
<td>TOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$130.00</td>
<td>$191.3K</td>
<td>969</td>
<td>370</td>
</tr>
<tr>
<td>DASH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/08/25</td>
<td>$247.50</td>
<td>$25.7K</td>
<td>151</td>
<td>253</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/08/25</td>
<td>$175.00</td>
<td>$80.4K</td>
<td>69</td>
<td>116</td>
</tr>
<tr>
<td>GME</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$40.00</td>
<td>$40.5K</td>
<td>953</td>
<td>75</td>
</tr>
<tr>
<td>WING</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$370.00</td>
<td>$74.4K</td>
<td>154</td>
<td>28</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$6000.00</td>
<td>$61.6K</td>
<td>22</td>
<td>1</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we notice a call option sweep that happens to be bearish, expiring in 3 day(s) on August 8, 2025. This event was a transfer of 210 contract(s) at a $310.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $108.1K, with a price of $515.0 per contract. There were 10646 open contracts at this strike prior to today, and today 49302 contract(s) were bought and sold. 
• For CVNA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), we notice a call option sweep that happens to be bearish, expiring in 31 day(s) on September 5, 2025. This event was a transfer of 275 contract(s) at a $425.00 strike. This particular call needed to be split into 20 different trades to become filled. The total cost received by the writing party (or parties) was $40.7K, with a price of $148.0 per contract. There were 14 open contracts at this strike prior to today, and today 2390 contract(s) were bought and sold. 
• For F (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), we notice a put option trade that happens to be neutral, expiring in 164 day(s) on January 16, 2026. This event was a transfer of 1800 contract(s) at a $9.67 strike. The total cost received by the writing party (or parties) was $70.2K, with a price of $39.0 per contract. There were 74322 open contracts at this strike prior to today, and today 1801 contract(s) were bought and sold. 
• Regarding BABA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), we observe a call option trade with bearish sentiment. It expires in 3 day(s) on August 8, 2025. Parties traded 197 contract(s) at a $118.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $133.0 per contract. There were 2194 open contracts at this strike prior to today, and today 986 contract(s) were bought and sold. 
• Regarding TOL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>), we observe a call option trade with bearish sentiment. It expires in 45 day(s) on September 19, 2025. Parties traded 299 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $191.3K, with a price of $640.0 per contract. There were 969 open contracts at this strike prior to today, and today 370 contract(s) were bought and sold. 
• Regarding DASH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>), we observe a put option trade with bullish sentiment. It expires in 3 day(s) on August 8, 2025. Parties traded 33 contract(s) at a $247.50 strike. The total cost received by the writing party (or parties) was $25.7K, with a price of $780.0 per contract. There were 151 open contracts at this strike prior to today, and today 253 contract(s) were bought and sold. 
• For AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we notice a call option trade that happens to be bearish, expiring in 3 day(s) on August 8, 2025. This event was a transfer of 20 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $80.4K, with a price of $4020.0 per contract. There were 69 open contracts at this strike prior to today, and today 116 contract(s) were bought and sold. 
• Regarding GME (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), we observe a call option trade with bearish sentiment. It expires in 864 day(s) on December 17, 2027. Parties traded 75 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $40.5K, with a price of $540.0 per contract. There were 953 open contracts at this strike prior to today, and today 75 contract(s) were bought and sold. 
• Regarding WING (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>), we observe a put option sweep with bearish sentiment. It expires in 45 day(s) on September 19, 2025. Parties traded 20 contract(s) at a $370.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $74.4K, with a price of $3720.0 per contract. There were 154 open contracts at this strike prior to today, and today 28 contract(s) were bought and sold. 
• For BKNG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), we notice a call option trade that happens to be bullish, expiring in 528 day(s) on January 15, 2027. This event was a transfer of 1 contract(s) at a $6000.00 strike. The total cost received by the writing party (or parties) was $61.6K, with a price of $61600.0 per contract. There were 22 open contracts at this strike prior to today, and today 1 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMZN

BABA

BKNG

CVNA

DASH

WING

10 Consumer Discretionary Stocks With Whale Alerts In Today's Session

Offerings

Press Releases

ProCap Acquisition Corp Announces the Pricing of Upsized $220,000,000 Initial Public Offering

ProCap Acquisition Corp Announces Closing of Upsized $250 Million Initial Public Offering

ProCap Acquisition Corp Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing July 11, 2025

PCAP

ProCap Acquisition

Comments

ProCap Acquisition

Interés en corto

ProCap Acquisition (NASDAQ:PCAPU) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL